- Home
- IVT vs NAMS Comparison
IVT vs NAMS Comparison
Compare IVT & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IVT
- NAMS
- Stock Information
- Founded
- IVT 2005
- NAMS 2019
- Country
- IVT United States
- NAMS Netherlands
- Employees
- IVT N/A
- NAMS N/A
- Industry
- IVT Real Estate Investment Trusts
- NAMS Biotechnology: Pharmaceutical Preparations
- Sector
- IVT Real Estate
- NAMS Health Care
- Exchange
- IVT Nasdaq
- NAMS Nasdaq
- Market Cap
- IVT 2.3B
- NAMS 2.2B
- IPO Year
- IVT N/A
- NAMS N/A
- Fundamental
- Price
- IVT $28.06
- NAMS $18.11
- Analyst Decision
- IVT Buy
- NAMS Strong Buy
- Analyst Count
- IVT 5
- NAMS 6
- Target Price
- IVT $31.75
- NAMS $42.83
- AVG Volume (30 Days)
- IVT 355.0K
- NAMS 694.5K
- Earning Date
- IVT 04-30-2025
- NAMS 05-08-2025
- Dividend Yield
- IVT 3.38%
- NAMS N/A
- EPS Growth
- IVT 140.80
- NAMS N/A
- EPS
- IVT 0.24
- NAMS N/A
- Revenue
- IVT $280,947,000.00
- NAMS $47,140,000.00
- Revenue This Year
- IVT $11.00
- NAMS N/A
- Revenue Next Year
- IVT $7.22
- NAMS N/A
- P/E Ratio
- IVT $116.55
- NAMS N/A
- Revenue Growth
- IVT 7.90
- NAMS 586.97
- 52 Week Low
- IVT $24.00
- NAMS $14.06
- 52 Week High
- IVT $31.65
- NAMS $27.29
- Technical
- Relative Strength Index (RSI)
- IVT 51.12
- NAMS 47.80
- Support Level
- IVT $27.01
- NAMS $16.79
- Resistance Level
- IVT $28.31
- NAMS $19.58
- Average True Range (ATR)
- IVT 0.42
- NAMS 0.94
- MACD
- IVT 0.01
- NAMS -0.12
- Stochastic Oscillator
- IVT 52.63
- NAMS 47.07
About IVT InvenTrust Properties Corp.
InvenTrust Properties Corp is the United States of America based company qualified as a REIT (Real Estate Investment Trust). It is focused on owning, leasing, redeveloping, acquiring and managing a multi-tenant retail platform. The company's wholly-owned and managed retail properties include grocery-anchored community and neighborhood centers and power centers, including those classified as necessity-based. InvenTrust operates through a single segment i.e. multi-tenant retail.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.